Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Endocrinology

• Publication date

  2004-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/EN.2003-1762PMID 15192042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical signals and biological responses elicited by the focal adhesion kinase.

  2001cited by this paper
• Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor

  2001cited by this paper
• c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinoma

  2000cited by this paper
• Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells.

  2000cited by this paper
• Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

  2000cited by this paper
• Hepatocyte Growth Factor (HGF) Stimulates Tumor Cells to Release Chemokines Active in Recruiting Dendritic Cells

  2000cited by this paper
• Role of morphogenetic factors in metastasis of mammary carcinoma cells

  1998cited by this paper
• Expression of the Hepatocyte Growth Factor and c-met in Normal Thyroid, Non-neoplastic, and Neoplastic Nodules

  1998cited by this paper
• Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

  1998cited by this paper
• In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer.

  1997cited by this paper
• Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.

  1997cited by this paper
• Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer.

  1995cited by this paper
• Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis.

  1995cited by this paper
• Hepatocyte growth factor/scatter factor induces a variety of tissue- specific morphogenic programs in epithelial cells

  1995cited by this paper
• Molecular basis of thyroid cancer.

  1994cited by this paper
• Scatter factor induces blood vessel formation in vivo.

  1993cited by this paper
• Effect of TSH in human thyroid cells: Evidence for both mitogenic and antimitogenic effects

  1992cited by this paper
• Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas.

  1992cited by this paper
• Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.

  1991cited by this paper
• C-terminal truncated forms of Met, the hepatocyte growth factor receptor

  1991cited by this paper
• Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor.

  1991cited by this paper
• Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors.

  1991cited by this paper
• De novo HLA class II and enhanced HLA class I molecule expression in SV40 transfected human thyroid epithelial cells.

  1991cited by this paper
• Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement.

  1989cited by this paper
• Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data.

  1988cited by this paper
• Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

  1987cited by this paper
• A simple, rapid, and sensitive DNA assay procedure.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid

  year unknowncited by this paper

• Overexpressed MET drives aggressive thyroid cancer phenotypes and serves as a precision therapeutic target

  2025cites this paper
• Turning tumor microenvironmental foes to friends: A new opportunity for thyroid cancer therapy and redifferentiation.

  2025cites this paper
• Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin

  2022cites this paper
• Development of metastatic poorly differentiated thyroid cancer from a sub-centimeter papillary thyroid carcinoma in a young patient with a germline MET mutation – association or random chance?

  2021cites this paper
• Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies

  2021cites this paper
• BRAF V600E Immunoexpression in Papillary Thyroid Carcinoma and Its Association with Prognostic Factors and Histopathologic Variant

  2021cites this paper
• Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application

  2020cites this paper
• Thyroid Cancer and Circadian Clock Disruption

  2020cites this paper
• The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives

  2018cites this paper
• Valproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathway.

  2017cites this paper
• Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

  2016cites this paper
• Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

  2016cites this paper
• Cabozantinib in Thyroid Cancer.

  2015cites this paper
• A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

  2014cites this paper
• Ekspresi Protein B-RAF Mutan pada Karsinoma Tiroid Papilifer yang Bermetastasis ke Kelenjar Getah Bening Regional

  2013cites this paper
• Autophagy and thyroid carcinogenesis: genetic and epigenetic links.

  2013cites this paper
• Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells

  2013cites this paper
• Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays

  2012cites this paper
• The pituitary tumor transforming gene in thyroid cancer

  2012cites this paper
• c-Met Inhibitor Synergizes with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Papillary Thyroid Carcinoma Cell Death

  2012cites this paper
• Role of genes differentially expressed in thyroid carcinogenesis

  2012cites this paper
• Signaling Pathways and Molecular Mediators in Metastasis

  2012cites this paper
• Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease

  2012cites this paper
• Targeted therapies for thyroid tumors

  2011cites this paper
• Development of c-MET pathway inhibitors

  2011cites this paper
• Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inh

  2011cites this paper
• Targeted Treatment of Differentiated and Medullary Thyroid Cancer

  2011cites this paper
• Biologically Targeted Therapies for Thyroid Cancers

  2011cites this paper
• “Self-Assisted” Amoeboid Navigation in Complex Environments

  2011cites this paper
• Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells

  2011cites this paper
• Contribution of PKB/AKT signaling to thyroid cancer.

  2011influential citation
• Targeted therapy of thyroid cancer.

  2010cites this paper
• Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

  2010cites this paper
• The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohisto-chemical characterization

  2010cites this paper
• olecular prognostic markers in papillary and follicular thyroid cancer : Current tatus and future directions

  2010cites this paper
• Cytokines, thyroid diseases and thyroid cancer.

  2010cites this paper
• Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.

  2010cites this paper
• Targeted therapy in radioiodine refractory thyroid cancer.

  2009cites this paper
• Molecularly targeted therapies for thyroid cancers.

  2009cites this paper
• Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.

  2009cites this paper
• Serum hepatocyte growth factor is increased in Hashimoto’s thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals

  2009cites this paper
• Tyrosine kinase inhibitors and the thyroid.

  2009cites this paper
• Cancer therapy using tumor-associated antigens to reduce side effects

  2009cites this paper
• Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases

  2008cites this paper
• Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma

  2008cites this paper
• Early clinical studies of novel therapies for thyroid cancers.

  2008cites this paper
• Receptor tyrosine kinase inhibitors in thyroid cancer.

  2008cites this paper
• Genome‐wide expression analysis of Middle Eastern papillary thyroid cancer reveals c‐MET as a novel target for cancer therapy

  2007cites this paper
• Expression of hepatocyte growth factor in Hashimoto's thyroiditis with nodular lesions.

  2007cites this paper
• Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers.

  2006cites this paper
• Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

  2006cites this paper
• The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid

  2005cites this paper
• The differentiation of benign and malignant thyroid nodules.

  2005cites this paper
• Cancer Biology and Signal Transduction Off-target Effects of C-met Inhibitors on Thyroid Cancer Cells

  year unknowncites this paper